• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Nimbolide inhibits tumor growth by restoring hepatic tight junction protein expression and reduced inflammation in an experimental hepatocarcinogenesis

    2021-01-15 09:01:28AmitKumarRamBalasubramaniyanVairappanBHSrinivas
    World Journal of Gastroenterology 2020年45期

    Amit Kumar Ram, Balasubramaniyan Vairappan, BH Srinivas

    Abstract

    Key Words: Hepatocellular carcinoma; Nimbolide; Tight junction; Inflammation; Oxidative stress; Zonula occludens 1 associated nucleic acid binding protein

    INTRODUCTION

    Hepatocellular carcinoma (HCC) is one of the most lethal malignancies and ranks third in the annual cancer mortality rate with overall 6-20 months of median survival after diagnosis[1]. The etiological factors such as hepatitis viral infection and alcohol abuse instigate chronic inflammation in the liver and lead to cirrhosis and ultimately HCC at the terminal stage[2]. The treatment modalities for HCC are limited with surgical resection and liver transplantation. The frequency of recurrence of HCC is high[1]. Since most of the HCC patients are diagnosed in an advanced stage, surgical options are unsuitable and only systemic chemotherapy (doxorubicin or sorafenib) and supportive care are the best available treatment options, however, only minimally increase the lifespan. Moreover, chemotherapy has low efficiency and side effects, and do not improve the 5-year survival rates[3]. Besides, due to the development of drug resistance and the existence of genetic heterogeneity within the individuals, the clinical outcome of targeted therapies is less effective[4]. Therefore, the discovery and development of successful new molecular chemotherapeutic agents targeting multiple pathways simultaneously are an immediate need to prevent the disease progression and recurrence in HCC patients.

    Tight junction (TJ) proteins are intercellular adhesion molecules located at the apical and basolateral membrane and play a fundamental role in maintaining tissue barrier and cellular integrity[5]. It regulates paracellular movement in endothelial cells, whereas in epithelial cells it tightly seals the gap between adjacent cells in an adhesive manner and prevents cell dissociation[6]. Of note, HCC is a type of epithelial cell carcinoma[7]. In the liver, TJ proteins are present in the hepatocytes and biliary epithelial cells, which form a blood-biliary barrier[8]. Zonula occludens (ZO)-1, a membrane-associated scaffolding protein that belongs to membrane associated guanylate kinase family, contains three PDZ domains, a single SH3 domain and a GK domain[9]. ZO-1 binds to occludin (transmembrane protein)viaits GK domain and interacts with homologous family members ZO-2 and ZO-3viathe second PDZ domain[10,11]. Apart from barrier function, TJs proteins have been implicated in cellular signal transduction to modulate cell proliferation and differentiation[12]. It has been found that SH3 domain of ZO-1 shares homology with SH3 domain of lethal disc large-1 tumor suppressor gene of drosophila, and its deletion or mutation leads to cell overgrowth and neoplastic changes, suggesting ZO-1 acts as a tumor suppressor[13]. ZO-1 binds to Y-box transcription factor ZO-1 associated nucleic acid binding protein (ZONAB), which interacts with the cell cycle kinase cyclin dependent kinase (CDK4), and regulates transcription of cell cycle related genes such as proliferating cell nuclear antigen (PCNA) and CyclinD1, providing a molecular link between ZO-1 and ZONAB, thereby regulating cellular proliferation[14,15]. Alteration in TJ proteins leads to a decrease in cell-cell adhesion, which is a crucial step to the cellular phenotypic transformation for tumor initiation and progression. Indeed, loss of TJ proteins such as ZO-1, occludin, and claudin have been shown to correlate with increased invasiveness, metastasis, and poor prognosis in breast cancer and colorectal cancer[16-18]. Similarly, although occludin-/-mice exhibited no gross anatomical defects, the gastric epithelial cells became hyperplastic after 40 wk[19]. Of note, our human study in HCC patients indicated a significant correlation between hepatic ZO-1 and high-sensitive C-reactive protein, however, the causal relationship remains unclear[20].

    Nimbolide is a tetranotriterpenoid, and an active compound isolated from leaves and flowers of the Neem tree (Azadirachta indica), which is a traditional medicinal plant of Meliaceae family which is widely distributed in Asia, Africa, and other tropical parts of the world[21]. Several published studies have shown evidence that nimbolide induces apoptosis, inhibits cell proliferation, and metastasis in a variety of cancer cells including prostate, breast cancer, and choriocarcinoma cell lines[22-24]. Furthermore, the antitumor activities of nimbolide have been shown to have beneficial effects in preclinical models of various cancers such as oral squamous cell carcinoma[25], prostate cancer, and pancreatic cancer[26,27]. Nimbolide also induces cell cycle arrest and apoptosis in renal cell carcinoma[28]and its antioxidant and anti-inflammatory activities were widely studied usingin vivoandin vitromodels[29,30]. In the current study, we aimed to investigate the effect of nimbolide on TJ protein expression, cell cycle progression, and inflammation in diethylnitrosamine (DEN) and N-nitrosomorpholine (NMOR) induced experimental HCC in mice.

    MATERIALS AND METHODS

    Materials

    DEN (N0756) and NMOR (N7382) were purchased from Sigma-Aldrich, St. Louis, Missouri, United States. Nimbolide of 97% purity (AHRF/NP/001) was procured from Asthagiri Herbal Research Foundation, Chennai, Tamilnadu, India. Doxorubicin hydrochloride (10 mg vial, Biochem pharmaceutical industries Ltd., Mumbai, India) was obtained from the Department of Medical Oncology, JIPMER.

    Animals and treatment procedure

    Male Swiss mice (CD-1 strain) weighing 10-15 g were obtained from the central animal facility, JIPMER, and maintained in a specific pathogen-free environment. All the animals were housed in polypropylene cages and maintained at 21-25 °C with 12 h light/dark cycle and free (ad libitum) access to water and standard rodent pellets. All experimental study was approved by JIPMER Institute Animal Ethics Committee and was carried out in accordance with the Committee for the Purpose of Control and Supervision of Experiments in Animals (CPCSEA) guidelines.

    Induction of HCC:Hepatocellular carcinoma was induced in mice by administering a single intraperitoneal (i.p.) injection of DEN [100 mg/kg body weight in phosphate buffer saline (PBS)] and subsequent administration of NMOR in the drinking water (80 ppm) for 28 wk. After tumor formation at 28thweek, the mice were randomized into five groups. Group I Naive mice continued to receive standard pellet diet and waterad libitumfor four weeks. Group II na?ve + treatment mice continued to receive standard pellet diet and waterad libitum, and were administered with nimbolide (6 mg/kg body weight in PBS) daily for four weeks through oral gavage. Group III HCC mice continued to receive standard pellet diet and waterad libitum, and were administered PBS (oral) for four weeks. Group IV HCC mice were administered with nimbolide (6 mg/kg body weight in PBS) daily for four weeks through oral gavage. Group V HCC mice were treated with the standard anticancer drug doxorubicin hydrochloride (1 mg/kg body weight in saline; i.p.) weekly thrice for the next four weeks to compare the chemotherapeutic efficacy of nimbolide. The final study groups were: (1) Na?ve (n= 8); (2) Na?ve + nimbolide (n= 8); (3) HCC (n= 10); (4) HCC + nimbolide (n= 10); and (5) HCC + doxorubicin (n= 10). The experimental protocol and treatment schedule is depicted in Figure 1A.

    At termination (end of 32ndweek) mice in different study groups were sacrificed by exsanguination under anaesthesia (ketamine hydrochloride 100 mg/kg). Blood was collected from the cardiac puncture in a heparinized tube, centrifuged at 3500 rpm at 4 °C for 10 min; plasma separated was stored at -80 °C for further analysis. After weighing liver tissues, parts of hepatic tumor nodules were excised, washed with PBS, and stored in 10% neutral buffered formalin for histopathological analysis, and the remaining liver tissue/nodules were snap-frozen in liquid nitrogen and stored in-80 °C for molecular studies.

    Morphological and histological assessment of liver tumor

    The entire visible and macroscopic nodules on the surface of the liver were counted for each mouse in all experimental groups. The length (L) and width (W) of superficial tumor nodules were measured by using a digital vernier caliper. The largest length (L) of the nodule was considered as the maximum tumor diameter. The volume of the tumor was calculated using the formula; volume (V) = L × (W)2/2. Tumor burden was calculated by multiplying mean tumor volume with the no. of nodules for each mouse in the experimental groups. Percentage tumor growth inhibition (% TGI) was defined as the difference between mean tumor volume (MTV) of DEN + NMOR treated (MTVD) and chemotherapeutic group (MTVT) at 32ndweek, using the formula: % TGI = [(MTVD - MTVT)/MTVD] × 100.

    For histopathological analysis, 10% formalin-fixed liver tissues were dehydrated with a series of graded alcohol, cleared in xylene, and embedded in paraffin wax. Thereafter, 5 μm tissue sections were cut and stained with hematoxylin and eosin (HE) with standard protocol. HE stained sections were assessed for histological features of HCC by an independent pathologist in a blind fashion. Numbers of mitotic cells in 10 high-power fields (HPF, 400 ×) were counted on HE stained slides and the highest number of mitotic cells among them was defined as the mitotic index.

    Analysis of liver function parameters and alpha-fetoprotein

    Plasma liver function parameters such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were measured by autoanalyzer using Beckman coulter kits (United States), according to manufacturer instruction. HCC tumor marker alpha-fetoprotein (AFP) was measured in plasma by ELISA kit (CKbio-15638; Shanghai, China).

    Western blotting

    Figure 1 Effect of nimbolide on body weight and liver coefficient in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A: Flowchart for the experimental hepatocarcinogenesis model; B: Average weekly body weight of na?ve and experimental mice; C: Liver coefficient of na?ve and experimental mice. All the data are expressed as mean ± SEM (n = 6-10). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison test post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. cP < 0.0001 compared to na?ve group; fP < 0.001 compared to hepatocellular carcinoma group. DEN: Diethylnitrosamine; HCC: Hepatocellular carcinoma; NMOR: N-nitrosomorpholine; PBS: Phosphate buffer saline.

    Liver tissues were snap-frozen in liquid nitrogen and stored at -80 °C for western blot analysis. About 150 mg of tissue was weighed and homogenized in 500 μL ice-cold RIPA buffer (G-Biosciences, St. Louis, MO, United States) with protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, MO, United States) and 10% protein methyl sulfonyl fluoride (in ethanol). Tissue homogenate was centrifuged at 14000 g for 10 min at 4 °C and supernatant was collected. The protein content of the individual sample was estimated by Bradford assay using the Pierce coomassie protein assay kit (23200, Thermo Fisher Scientific, Rockford, IL, United States). About 30 μg of total protein of individual sample was diluted in SDS sample buffer and were resolved using SDS-polyacrylamide gel electrophoresis and blotted onto a nitrocellulose membrane (S045A330R, Advantec, Tokyo, Japan). Then the membranes were blocked for non-specific binding with 5% non-fat dry milk (GRM1254; Himedia, Mumbai, India) in Tris-buffered saline containing 0.01% Tween 20 (TBST) for 1 h at room temperature, followed by overnight incubation with primary antibody at 4 °C. The primary antibodies used were rabbit polyclonal anti-ZO1 (1:1000, 61-7300; Thermo Fisher, Rockford, IL, United States), rabbit polyclonal anti-ZONAB (1:500, 40-2800; Thermo Fisher, Rockford, IL, United States), mouse monoclonal anti-occludin (1:1000, sc-133256; Santa Cruz, Dallas, TX, United States), rabbit polyclonal anti-CDK4 (1:1000, A0366; Abclonal, Woburn, Massachusetts, United States), rabbit polyclonal anti-CyclinD1 (1:1000, A2708; Abclonal, Woburn, MA, United States), rabbit monoclonal anti-nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB)p65 (1:1000, 8242S; CST, Danvers, MA, United States), rabbit polyclonal anti-tumor necrosis factor alpha (TNF-α) (1:1000, 2081R; BIOSS, Woburn, Massachusetts, United States), rabbit polyclonal anti-Interleukin 1 beta (IL-1β) (1:1000, A11370; Abclonal, Woburn, MA, United States) and mouse monoclonal anti-β-actin (1:1000, AC004; Abclonal, Woburn, MA, United States). After overnight incubation, membranes were washed with TBST three times and incubated with peroxidase-conjugated goat antirabbit (1:10000, 406401; BioLegend, San Diego, CA, United States) or goat anti-mouse (1:10000, 405306; BioLegend, San Diego, CA, United States) for 1 h at room temperature and the bands were visualized using an enhanced chemiluminescent substrate (34087; West pico detection kit, Thermo Scientific, Rockford, IL, United States) in Chemidoc system (Bio-rad, United States). Protein bands were quantified using Image Lab software (Bio-rad, United States).

    Immunohistochemistry

    3-5 μm thick sections were cut using an automated microtome (Leica Biosystems) and mounted on a silane coated slide. After deparaffinization, slides were immersed in xylene and rehydrated in different graded ethanol followed by 3% H2O2in methanol for 15 min to quench the endogenous peroxidase activity. Then the sections were rinsed with PBS, and antigen retrieval was performed using citrate buffer (PH = 6.0) in the decloaking system at 110°C for 10 min. After blocking, the sections were incubated with primary antibody overnight at 4°C. Primary antibodies used were rabbit polyclonal anti-glypican-3 (1:100, A13988; Abclonal, Woburn, MA, United States), rabbit polyclonal anti-PCNA (1:100, A0264; Abclonal, Woburn, MA, United States), and rabbit polyclonal anti-4-Hydroxynonenal (4HNE) (1:100, bs-6313R; Bioss, Woburn, Massachusetts, United States). After washing with PBS, sections were incubated with universal anti-mouse/rabbit Ig (MP-7500; Vector lab, Burlingame, CA, United States) for 30 min at room temperature and immunostaining was performed with ImmPACT DAB kit (SK4105; Vector lab, Burlingame, CA, United States) and counterstained with hematoxylin. After mounting with Histamount solution, sectioned were examined under EVOS FLc imaging system (Life Techonologies, United States).

    Molecular docking analysis

    Molecular docking using Schodinger AutoDock 4.0 software (United States) was performed to predict the binding affinity of nimbolide with ZO-1, NF-κB, and TNF-α. The X-ray crystal structure of ZO-1 [Protein Data Bank archive (PDB) ID: 2RRM], NFκB (PDB ID: 1VKX), and TNF-α (PDB ID: 2TNF) were retrieved from RCSB protein data bank (http://www.rcsb.org). The proteins were prepared before molecular docking using PyMol software (Schrodinger LLC, Cambridge, United States). Nimbolide (CID: 100017) 2D structure was retrieved from the Pubchem database (https://pubchem.ncbi.nlm.nih.gov/compound) in SDF file format and then converted to .mol2 format using Open Babel software version 2.4.1. After the simulation, different docked conformations were obtained and conformation with the strongest binding affinity towards ligand binding cavity of ZO-1, NF-κB, and TNF-α were selected as possible binding conformations and taken for further analysis. The final assessment of protein-ligand interaction was done and interpreted as Glide score (kcal/moL).

    Statistical analysis

    All the data are expressed as mean ± standard error of mean (SEM). Results were analyzed using GraphPad Prism 6.0 software. The comparison between different groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or by Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. AP< 0.05 was considered as statistical significance.

    RESULTS

    Effect of nimbolide on body weight, liver weight and liver coefficient in DEN/NMOR induced HCC mice

    Experimental mice were treated with nimbolide or doxorubicin (Figure 1A) and the average weekly bodyweight of the naive and experimental mice was represented in Figure 1B. HCC induction in mice showed a decreased bodyweight throughout the experimental period compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed a trend in increased body weight from 28thto 32ndweek (P= 0.6781) (Figure 1B). Furthermore, the liver/body weight ratio measured was higher (P< 0.0001) in HCC mice compared to na?ve mice and this may be due to the induction of tumors by DEN and NMOR. On the contrary, treatment with nimbolide to HCC mice showed reduced liver/body weight ratio (P< 0.001) when compared to DEN/NMOR induced HCC mice, suggesting nimbolide possibly alleviated tumor burden (Figure 1C). Similar effects were seen in mice treated with doxorubicin in DEN/NMOR induced HCC mice (Figure 1C). Na?ve mice treated with nimbolide shows similar body weight and liver/body weight ratio when compared to the na?ve mice alone group.

    Nimbolide inhibits DEN/NMOR induced hepatocarcinogenesis

    Macroscopically visible hepatic nodules were evident on the liver surface of HCC mice, whereas, treatment with nimbolide or doxorubicin showed much lesser hepatic nodules (Figure 2A). Moreover, the maximum tumor diameter measured was higher in HCC mice and was reduced following treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice (Figure 2B). The calculated tumor burden was also higher in HCC mice. Treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice showed reduced tumor burden compared to HCC mice alone group (Figure 2C). Also, nimbolide or doxorubicin treatment to HCC mice inhibited tumor growth by 52.08% and 54.45%, respectively, with the reduction in mean tumor volume (P< 0.01) compared to HCC mice alone group (Table 1).

    To identify the effective dose of nimbolide, we performed a dose-response study with three different doses of nimbolide (1.5 mg/kg, 3 mg/kg, and 6 mg/kg body weight) in DEN/NMOR induced HCC mice. We found treatment with 6 mg/kg nimbolide reduced maximum tumor diameter (P< 0.05) (Supplementary Figure 1) and tumor volume (P< 0.05) (Supplementary Figure 2) in HCC mice, while 1.5 mg/kg and 3 mg/kg nimbolide treatment were not significant compared to HCC mice alone group. Liver function parameters and AFP levels were also significantly decreased to HCC mice following 6 mg/kg b.w. nimbolide treatment (Supplementary Table 1). Based on the above preliminary data, the effective dose of 6 mg/kg b.w. nimbolide was chosen for subsequent experiments.

    To confirm the malignancy potential of DEN/NMOR induced hepatocarcinogenesis, representative hematoxylin and eosin stained sections of the liver was studied and the results were shown in Figure 2D. Naive (Figure 2D, panel a) and na?ve + nimbolide (Figure 2D, panel b) mice liver showed normal hepatic lobular architecture whereas, HCC mice liver showed neoplastic changes (Figure 2D, panel c). The neoplastic changes in the liver showed classical features of HCC characterized by hepatocyte arranged in cords (3 cell layer), cellular atypia, eosinophilic to clear cytoplasm, enlarged nucleus, and hyperchromasia. Treatment with nimbolide or doxorubicin showed minimal cellular atypia and decreased nuclear: Cytoplasmic ratio (Figure 2D, panel d and e). Furthermore, the mitotic index is a simple method for the evaluation of cellular proliferation rate and is a hallmark feature of cancer. Indeed, the mitotic index is a predictor of prognosis in patients with HCC[31]. Hematoxylin and eosin stained liver section of HCC mice showed a higher mitotic index (3-4/10 HPF) whereas, a lower mitotic index (1-2/10 HPF) was observed in nimbolide or doxorubicin treated HCC mice liver (Table 2).

    Effect of nimbolide on liver function parameters and tumor and cell proliferation markers in DEN/NMOR induced HCC mice

    Elevated levels of hepatic dysfunction marker enzymes such as AST, ALT, and ALP are widely used to assess hepatic dysfunction, and are associated with HCC progression[32]. DEN/NMOR induced HCC mice showed elevated levels of AST, ALT, and ALP (P< 0.0001) when compared to naive mice. Treatment with nimbolide or doxorubicin to HCC mice lowered the plasma levels of AST, ALT, and ALP (P< 0.01) compared to HCC mice alone group (Figure 3A-C). Plasma alpha-fetoprotein (AFP) levels and glypican-3 are clinically used as tumor markers for the diagnosis and prognosis of HCC[33,34]. Reduced AFP levels was reported to have prognostic significance after hepatic tumor resection and transarterial chemoembolization in HCC patients[35,36]. We found a higher plasma AFP levels in HCC mice (P< 0.0001) compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed decreased plasma AFP levels (P< 0.01) compared to HCC mice alone group (Figure 3D). Increased hepatic glypican-3 expression was associated with a significantly lower 5-year survival rate and poor prognosis in HCC patients[34]. Figure 3E shows the immunostaining of glypican-3 on the liver sections of naive and experimental mice.Naive mice (Figure 3E, panel a) and na?ve + nimbolide mice (Figure 3E, panel b) liver showed negative reactivity to glypican-3 whereas, strong glypican-3 cytoplasmic positivity was seen in HCC mice liver (Figure 3E, panel c), while nimbolide or doxorubicin treatment to HCC mice showed reduced glypican-3 cytoplasmic positivity (Figure 3E, panel d and e). Quantification of glypican-3 positive cells in the experimental group was represented in Figure 3F. PCNA is a putative marker for cell proliferation and hepatocyte damage and its high expression was associated with poor survival in HCC patients[37]. Figure 3G shows the immunostaining of PCNA on the liver sections of naive and experimental mice. Negative staining was observed in na?ve (Figure 3G, panel a) and na?ve + nimbolide (Figure 3G, panel b) mice liver whereas, HCC mice liver (Figure 3G, panel c) displayed much higher PCNA-positive nuclei, while treatment with nimbolide (Figure 3G, panel d) or doxorubicin (Figure 3G, panel e) to HCC mice showed reduced PCNA-positive nuclei. Quantification of PCNA positive nuclei in the experimental group was represented in Figure 3H.

    Table 1 Mean tumor volume and tumor growth inhibition (%) in the experimental mice

    Table 2 Mitotic index in the na?ve and experimental mice

    Nimbolide ameliorates hepatic inflammation and oxidative stress in DEN/NMOR induced HCC mice

    Figure 4A-C shows the hepatic NF-κB, TNF-α, and IL-1β protein expressions by western blot in the naive and experimental mice. The hepatic protein expression of NF-κB (P< 0.01), IL-1β (P<0.001), and TNF-α (P< 0.01) were increased in HCC mice compared to naive mice. Nimbolide or doxorubicin treatment to HCC mice showed decreased NF-κB (P< 0.05), IL-1β (P< 0.05), and TNF-α (P< 0.05) protein expressions compared to HCC mice alone. Figure 4D shows immunostaining of 4HNE on the liver sections of naive and experimental mice. Naive (Figure 4D, panel a) and na?ve + nimbolide (Figure 4D, panel b) mice liver showed negative reactivity to 4HNE while 4HNE expression has increased in HCC mice liver (Figure 4D, panel c). Nimbolide (Figure 4D, panel d) or doxorubicin (Figure 4D, panel e) treatment to HCC mice showed reduced hepatic 4HNE nuclear positivity compared to HCC mice alone. Moreover, 4HNE positive nuclei quantification was done and represented in Figure 4E.

    Nimbolide treatment attenuates hepatic ZONAB and cell cycle markers proteins expression in DEN/NMOR induced HCC mice

    Figure 2 Nimbolide inhibits diethylnitrosamine and N-nitrosomorpholine induced hepatocarcinogenesis. A: Macroscopic images of mice liver from na?ve and experimental groups; B: Maximum tumor diameter in na?ve and experimental groups; C: Tumor burden in na?ve and experimental groups; D: Representative images of hematoxylin and eosin stained liver sections from naive and experimental groups (200 × magnification). Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 6-7). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. dP < 0.05 compared to hepatocellular carcinoma group. HCC: Hepatocellular carcinoma.

    Figure 5A shows the hepatic ZONAB protein expression by western blot in naive and experimental mice. The hepatic ZONAB protein expression was higher (P< 0.0001) in HCC mice compared to naive mice while treatment with nimbolide (P< 0.001) or doxorubicin (P< 0.01) to HCC mice showed reduced ZONAB protein expression compared to HCC mice alone. Figure 5B and C shows the cell cycle markers CDK4 and CyclinD1 protein expressions by western blot in naive and experimental mice. The hepatic CDK4 (P< 0.01) and CyclinD1 (P< 0.001) protein expressions were increased in HCC mice compared to naive mice. Treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice showed decreased CDK4 and cyclinD1 protein expression compared to HCC mice alone.

    Nimbolide treatment restores hepatic tight junction protein expressions in DEN/NMOR induced HCC mice

    Figure 6A shows the hepatic occludin protein expression by western blot in naive and experimental mice. The hepatic occludin protein expression was down-regulated (P< 0.01) in HCC mice compared to naive mice while treatment with nimbolide (P< 0.05) or doxorubicin (P< 0.05) to HCC mice, occludin protein expression was up-regulated compared to HCC mice alone. Figure 6B shows the hepatic ZO-1 protein expression by western blot in naive and experimental mice. Moreover, hepatic ZO-1 protein expression was reduced (P< 0.01) in HCC mice compared to naive mice. Nimbolide (P< 0.05) or doxorubicin (P< 0.05) treatment to HCC mice showed significantly increased ZO-1 protein expression when compared to lone HCC.

    Nimbolide has a higher binding affinity towards ZO-1, NF-κB, and TNF-α proteins

    Figure 3 Effect of nimbolide on liver function parameters and tumor and cell proliferation markers in diethylnitrosamine and Nnitrosomorpholine induced hepatocellular carcinoma mice. A: Plasma aspartate aminotransferase level in na?ve and experimental groups; B: Plasma alanine aminotransferase level in na?ve and experimental groups; C: Plasma alkaline phosphatase level in na?ve and experimental groups; D: Plasma alphafetoprotein level in na?ve and experimental groups; E: Representative images of glypican-3 immunostaining of mice liver from naive and experimental groups (200 × magnification); F: Quantification of glypican-3 positive cells in experimental groups by counting five 400 × fields of each liver section; G: Representative images of proliferating hepatocytes by proliferating cell nuclear antigen (PCNA) immunostaining of mice liver from naive and experimental groups (200 × magnification); H: Quantification of PCNA positive nuclei in experimental groups by counting five 400 × fields of each liver section. Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 3-6). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. cP < 0.0001 compared to na?ve group; dP < 0.05, eP < 0.01 compared to hepatocellular carcinoma group. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; PCNA: Proliferating cell nuclear antigen; HPF: High-power fields; HCC: Hepatocellular carcinoma.

    The 2D structure of nimbolide is represented in Supplementary Figure 3. The 3D structure and ligand binding cavity of ZO-1, NF-κB, and TNF-α was shown in Supplementary Figure 4A-F. Docked complexes of nimbolide and ZO-1 protein showed nimbolide formed hydrogen bonds with amino acid residues Arg 757, Lys 760, Asn 764, Asn 765 and hydrophobic interaction with amino acid residues Ala 623, Pro 710, Lys 760, Leu 761 towards predicted ligand-binding cavity of ZO-1 with a glide score of -9.28 kcal/moL which indicates nimbolide has a strong binding affinity and modulatory effect on ZO-1 protein (Figure 7A-C and Table 3). Molecular docking also revealed nimbolide formed hydrogen bonds with amino acid residues Lys 28, Arg 33, Ser 45 and hydrophobic interaction with amino acid residues Arg 33, Arg 35, Pro 47 towards predicted ligand-binding cavity of NF-κB protein with a glide score of -7.62 kcal/moL suggesting nimbolide has a modulatory effect on NF-κB protein (Figure 7DF and Table 3). Besides, nimbolide also formed hydrogen bonds with amino acid residues Lys 98, Tyr 119 and hydrophobic interaction with amino acid residues Ala 96, Pro 117, Ile 118, Tyr 119 towards predicted ligand-binding cavity of TNF-α protein with a glide score of -8.84 kcal/moL indicating nimbolide has a strong binding and modulatory effect on TNF-α protein (Figure 7G-I and Table 3).

    DISCUSSION

    Our study showed for the first time that nimbolide treatment to DEN and NMOR induced HCC mice exhibits anticancer effect as evidenced by decreased plasma AFP levels and hepatic glypican-3 expression, inhibition of cell cycle progression (ZONAB, CDK4, and cyclinD1), and amelioration of inflammation and oxidative stress. Nimbolide treatment also reduced tumor size, tumor burden, and pathological grade in HCC mice. The other major finding of the current study is increased TJ proteins such as ZO-1 and occludin following treatment with nimbolide to HCC mice. Further, the molecular docking study revealed that nimbolide formed several hydrogen bonds and hydrophobic interactions with amino acid residues of ligand binding cavity ofZO-1, NF-κB, and TNF-α, showing higher binding affinity as observed by high glide score between the docked complexes.

    Table 3 Binding affinity and interaction of nimbolide with different amino-acid residues of zonula occludens 1, nuclear factor of kappa light polypeptide gene enhancer in B-cells and tumor necrosis factor alpha proteins. Binding affinity is represented as Glide score (kcal/moL)

    Doxorubicin is a standard anticancer drug that was also administered to HCC mice to compare the effectiveness of nimbolide. Our results revealed that almost 52.08% of tumor growth was inhibited by nimbolide, whereas doxorubicin inhibited 54.45% tumor growth in HCC mice. Additionally, reduction in liver coefficient, tumor diameter, tumor burden, and tumor volume in HCC mice by nimbolide treatment was also comparable with the standard anticancer drug doxorubicin.

    A key finding of this study was that nimbolide treatment improved hepatic TJ protein (ZO-1 and occludin) expression in HCC mice. Our previous human study showed evidence that decreased hepatic ZO-1 expression was positively correlated with disease severity in HCC patients[20]. Moreover, occludin was also found to be decreased in HCC patients[38]. Of note, our previous study also showed evidence that cirrhotic mice brain exhibited significantly decreased ZO-1, occludin, and claudin-5 protein expression, which were associated with increased inflammation observed in cirrhotic mice[39,40]. The TJ protein ZO-1 has been reported to be involved in cell proliferation[12]. ZO-1 knock-down in mice showing embryonically lethal and was associated with defective angiogenesis of the yolk sac and impaired apoptosis of the embryonic cells[41]. Besides, the deletion of ZO-1 showed increased cell proliferation and neoplastic changes which suggests ZO-1 may have a tumor suppressor role[13]. In this context, lycopene (carotenoid) administration inhibited human cutaneous squamous cell carcinoma (cSCC) cell proliferation by up-regulating ZO-1 expression[42]. Moreover, earlier studies have suggested that ZO-1 regulates cell proliferation by binding to ZONAB, a Y-box transcription factor that has DNA binding element inverted CCAAT box, whose nuclear accumulation leads to transcription of cell cycle related genes such as CDK4, Cyclin D1, and PCNA[14,15]. This was supported by the fact that, in a sparse culture where the proliferation rate is high, the cellular ZONAB expression is high and the ZO-1 expression is low. By contrast, the ZONAB expression is down-regulated and ZO-1 expression is up-regulated in the confluent quiescent monolayer cells[43]. Knock-down of ZO-1 or overexpression of ZONAB resulted in increased proliferation of retinal pigment epithelial cells and induced epithelial to mesenchymal transition phenotype in mice[44]. In the present study, we found increased hepatic protein expression of ZONAB and its transcriptionally regulated cell cycle mediators such as CDK4, cyclinD1, and PCNA expressions in HCC mice, which were decreased following nimbolide treatment. Furthermore, we noted a reciprocal relationship between the protein expression pattern of ZO-1 and ZONAB in HCC mice which was reversed by nimbolide treatment. Thus, our study demonstrated for the first time that ZO-1/ZONAB pathway plays a crucial role in the pathogenesis of HCC by regulating cell cycle progression. Moreover, we also identified that nimbolide interacts with the ligand-binding cavity of ZO-1, forming hydrogen bonds and hydrophobic interaction with amino acids which may have a modulatory effect.

    Figure 4 Nimbolide ameliorates hepatic inflammation and oxidative stress in diethylnitrosamine and N-nitrosomorpholine hepatocellular carcinoma mice. A-C: Hepatic protein expression levels of nuclear factor of kappa light polypeptide gene enhancer in B-cells, interleukin 1 beta and tumor necrosis factor alpha by western blot in naive and experimental groups; D: Representative images of 4-Hydroxynonenal (4HNE) immunostaining of mice liver from naive and experimental groups (200 × magnification); E: Quantification of 4HNE positive nuclei in experimental groups by counting five 400 × fields of each liver section. Scale bar: 200 μm; all the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01, bP < 0.001 compared to na?ve group; dP < 0.05, eP < 0.01 compared to hepatocellular carcinoma group. NF-κB: Nuclear factor of kappa light polypeptide gene enhancer in B-cells; IL-1β: Interleukin 1 beta; TNF-α: Tumor necrosis factor alpha; 4HNE: 4-Hydroxynonenal; HCC: Hepatocellular carcinoma.

    Another finding in our study is that nimbolide could regulate cell cycle progression in DEN and NMOR induced HCC in mice. Cell cycle is a major event for cell proliferation and an uncontrolled tumor cell proliferation is responsible for HCC progression[45,46]. CDK4 and cyclinD1 are important mediators of cell cycle progression which are found to be overexpressed and associated with poor prognosis in HCC patients[45,46]. In the presence of extracellular stimuli such as cytokines (TNF-α), the active complex is formed by CDK4/CyclinD1 which phosphorylates retinoblastoma protein (pRb), and promotes the transition of the cell cycle from G1 to S phase through the restriction (R) checkpoint. The pRb induces gene expression necessary for DNA replication such as PCNA during S phase[47]. A previous study has shown that nimbolide regulates cell cycle progression in both cell lines and animal models[48]. In glioblastoma, nimbolide inhibited CDK4/CDK6 kinase activity and arrested cell cycle at the G1 phase[49]. Priyadarsiniet al[50]reported that in HeLa cells nimbolide treatment inhibited major cell cycle regulatory proteins such as cyclin D1, cyclin B, and PCNA and restricted cell cycle at G0/G1 phase[50]. Concurrent with the above studies, we also observed that nimbolide treatment reduces CDK4 and Cyclin D1 protein expression in HCC mice. Therefore, we speculate that nimbolide could inhibit cell proliferation by preventing cell cycle progression from G1 to S phase and prevents HCC pathogenesis.

    In the current study, we found nimbolide might dampen the inflammation through NF-κB pathway in HCC mice. Inflammation has a wide impact on the pathogenesis of cancer development starting from initiation to progression and metastasis. 70% of HCC develops in cirrhotic patients on the background of inflammation[1]. Activation of the NF-κB pathway plays a critical role in inflammation-induced cancer by affecting cell proliferation, apoptosis, angiogenesis, and metastasis[2]. Stimulation of hepatic kupffer cells during chronic inflammation releases proinflammatory cytokines such as TNF-α and IL-1βviathe NF-κB pathway which is known to regulate cell proliferation, survival, and inhibition of apoptosis[2]. In this study, we found increased hepatic protein expression of NF-κB and its downstream mediator proinflammatory cytokines TNF-α and IL-1β in HCC mice, indicating the hyperinflammatory state of hepatic tissue. A previous study indicated that nimbolide administration inhibits NF-κB signaling and proinflammatory cytokines in both cell lines and animal models[48]. In line with this evidence, Kavithaet al[51]reported that nimbolide exerts anticancer effects in HepG2 cells by inhibiting NF-κB signaling and its downstream mediator Wnt/βcatenin pathway[51]. Similarly, Guptaet al[52]reported that nimbolide treatment inhibited xenograft progression in colorectal cancer by targeting the NF-κB pathway and by suppressing pro-inflammatory microenvironment[52]. Concomitant with the above results we also proved that nimbolide treatment attenuated the protein expression of NF-κB, TNF-α, and IL-1β in HCC mice. Moreover, molecular docking study revealed that nimbolide formed hydrogen bonds and hydrophobic interaction with amino acid residues of the ligand binding cavity of NF-κB and TNF-α. These results suggest that nimbolide ameliorated inflammation and suppressed NF-κB signaling in DEN and NMOR induced HCC mice. Therefore it is postulated that nimbolide might regulate cell proliferation by targeting the NF-κB signaling pathway which is considered as a central pathway linking inflammation and cancer[2]. The proposed mechanism of action by which nimbolide exerts its therapeutic effects in HCC mice is depicted in Figure 8.

    DEN is known to induce HCC by generating reactive oxygen species (ROS) which causes oxidative stress in the cell leading to oxidative DNA damage, membrane lipid peroxidation, and mitochondrial damage favoring cell survival and proliferation[53]. 4HNE, a potent and stable by-product of lipid peroxidation, is considered as a marker of oxidative stress, and can independently form DNA adducts, and causes mutation and genetic instability, thus favoring hepatocarcinogenesis[54]. In the current study, we found increased nuclear 4HNE protein expression in HCC mice liver while nimbolide treatment to HCC mice significantly reduced hepatic 4HNE protein expression. This suggests that nimbolide could protect ROS induced oxidative damage and lipid peroxidation in HCC. In this context, Alshammariet al[29]reported that nimbolide treatment abrogates oxidative stress and promotes antioxidants capacity in the primary hepatocytes[29]. Similarly, another study in DMBA induced oral cancer showed that nimbolide inhibited oxidative stress-induced DNA damage by improving antioxidant enzymes[30]. Thus, collectively our results indicate that nimbolide has a potent antioxidant activity and abrogates oxidative stress by quenching free radicals and might restore cellular redox balance thereby attenuating the progression of carcinogenesis. Our study has some limitations that we did not study the nimbolide effects in ZO-1 or ZONAB conditional knock-out mice to prove the exact mechanism of HCC regulation. Indeed, our future experimental approach would delineate this eitherin vivoor in vitro. Moreover, with data obtained in this work, it is not possible to establish the mechanisms involved in the anticancer effect of nimbolide. The study show different mechanisms that occur at the same time than the anticancer effect but a direct relationship between them has not been showed. The efficacy of doxorubicin is very limited in the treatment of human HCC so a limited effect of nimbolide could be also expected.

    Figure 5 Nimbolide treatment attenuates hepatic zonula occludens 1 associated nucleic acid binding protein and cell cycle markers proteins expression in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A: Hepatic protein expression levels of zonula occludens 1 associated nucleic acid binding protein by western blot in naive and experimental groups; B: Hepatic protein expression levels of cyclin dependent kinase 4 by western blot in naive and experimental groups; C: Hepatic protein expression levels of CyclinD1 by western blot in naive and experimental groups. All the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01, bP < 0.001, cP < 0.0001 compared to na?ve group; dP < 0.05, eP < 0.01, fP < 0.001 compared to HCC group. ZONAB: Zonula occludens 1 associated nucleic acid binding protein; CDK4: Cyclin dependent kinase; HCC: Hepatocellular carcinoma.

    CONCLUSION

    In conclusion, the results of our study showed evidence in HCC mice that nimbolide treatment suppresses tumor growth and cell cycle progression, and ameliorates inflammation and oxidative stress. Importantly, nimbolide treatment restored hepatic TJ proteins expression and regulates ZO-1/ZONAB pathway in HCC. Our study also demonstrated that the anticancer efficiency of nimbolide was comparable with standard anticancer drug doxorubicin in a preclinical model of HCC. Treatment with natural bioactive compounds, therefore, represents promising chemoprevention agents with minimal side effects, and thus nimbolide could be used as a novel potential candidate drug against HCC progression. Indeed, further molecular and population-based studies are warranted.

    Figure 6 Nimbolide treatment restores hepatic tight junction protein expression in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. A and B: Hepatic protein expression levels of occludin and zonula occludens 1 by western blot in naive and experimental groups. All the data are expressed as mean ± SEM (n = 3). The comparison between the groups was analyzed by one-way ANOVA followed by Tukey’s multiple comparison post-hoc test or Kruskal-Wallis followed by Dunn’s multiple comparison post-hoc test. aP < 0.01 compared to na?ve group; dP<0.05 compared to hepatocellular carcinoma group. ZO-1: Zonula occludens 1; HCC: Hepatocellular carcinoma.

    Figure 7 Molecular docking analysis of nimbolide with zonula occludens 1, nuclear factor of kappa light polypeptide gene enhancer in Bcells and tumor necrosis factor alpha. A and B: Representation of nimbolide and zonula occludens 1 (ZO-1) docking complex; C: Interaction of nimbolide with amino acid residues of ZO-1; D and E: Representation of nimbolide and nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB) docking complex; F: Interaction of nimbolide with amino acid residues of NF-κB; G and H: Representation of nimbolide and tumor necrosis factor alpha (TNF-α) docking complex; I: Interaction of nimbolide with amino acid residues of TNF-α.

    Figure 8 Schematic representation of the mechanism of action of nimbolide in diethylnitrosamine and N-nitrosomorpholine induced hepatocellular carcinoma mice. Nimbolide treatment inhibits tumor growth in diethylnitrosamine and N-nitrosomorpholine induced Hepatocellular carcinoma (HCC) mice by targeting tight junctions (TJs) proteins [Zonula occludens-1 (ZO-1) and Occludin]. Nimbolide mediated up-regulation of ZO-1 represses the transcriptional activity of ZO-1 associated nucleic acid binding protein at a junctional site preventing its nuclear accumulation and thus preventing the induction of cell cycle related genes cyclin dependent kinase 4, cyclinD1 and proliferating cell nuclear antigen. Nimbolide treatment also restores barrier integrity by up-regulation TJs proteins which prevent translocation of growth factors and nutrients necessary for cell growth from apical to the basolateral domain. Further, nimbolide also targets the nuclear factor of kappa light polypeptide gene enhancer in B-cells pathway ameliorating inflammation in HCC mice. ZO-1: Zonula occludens 1; ZONAB: ZO-1 associated nucleic acid binding protein; CDK4: Cyclin dependent kinase; PCNA: Proliferating cell nuclear antigen; NF-κB: Nuclear factor of kappa light polypeptide gene enhancer in B-cells; IL-1β: Interleukin 1 beta; TNF-α: Tumor necrosis factor alpha; HCC: Hepatocellular carcinoma.

    ARTICLE HIGHLIGHTS

    Research background

    Worldwide, hepatocellular carcinoma (HCC) is a prevalent lethal disease exhibiting the highest cancer mortality rate with limited chemotherapeutic options. The discovery of a new chemotherapeutic agent is an urgent demand for the treatment of HCC patients.

    Research motivation

    Tight Junction (TJ) proteins have been implicated to regulate various signal transductions in carcinogenesis. Recent evidence has shown that nimbolide possesses anticancer activity in various cancers; however, its specific mechanism in HCC remains elusive.

    Research objectives

    We aimed to study the effect of nimbolide on TJ proteins, cell cycle progression, and hepatic inflammation in an experimental hepatocarcinogenesis mouse model.

    Research methods

    Diethylnitrosamine (DEN) and N-nitrosomorpholine (NMOR) induced mouse model of HCC was performed in the present study. Nimbolide was given orally for four consecutive weeks to DEN/NMOR induced HCC mice from 28thto 32ndweek. At the end of the study period (32ndweek), all the mice were sacrificed, blood and liver samples were collected for various analysis. HCC tumor markers such as alphafetoprotein (AFP) levels and glypican-3 protein expression were analysed. Hepatic TJ proteins, cell cycle, and inflammatory marker protein expressions were evaluated by western blot analysis. Cell proliferation and oxidative stress markers were analyzed by immunohistochemistry. Molecular docking study was performed to confirm the interaction of nimbolide with zonula occludens 1 (ZO-1), nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB) and tumor necrosis factor alpha (TNF-α).

    Research results

    Hepatic tumor size and HCC tumor markers AFP and glypican-3 were reduced following nimbolide treatment. TJ protein (ZO-1 and occludin) expression levels were restored after nimbolide treatment, while ZO-1 associated nucleic acid binding protein expression was attenuated. Additionally, nimbolide treatment also reduced cell proliferation and cell cycle markers. Moreover, nimbolide treatment ameliorated hepatic inflammation and oxidative stress in HCC mice. The binding affinity and modulatory effects of nimbolide with ZO-1, NF-κB, and TNF-α were confirmed by molecular docking analysis.

    Research conclusions

    Nimbolide treatment showed anticancer effects by improving TJ proteins expression, suppressing cell cycle and cell proliferation, and ameliorating inflammation and oxidative stress in DEN and NMOR induced HCC mice.

    Research perspectives

    Nimbolide may be used as a potential chemotherapeutic agent for HCC treatment. Further molecular research and human studies may delineate nimbolide as a candidate drug for HCC treatment.

    ACKNOWLEDGEMENTS

    We thank Dr. Athithan V, PhD, for analyzing molecular docking studies.

    亚洲欧美成人综合另类久久久 | 精品人妻一区二区三区麻豆| 亚洲精华国产精华液的使用体验| 欧美日本视频| 2022亚洲国产成人精品| 久久久成人免费电影| 婷婷色综合大香蕉| 精品熟女少妇av免费看| 国产毛片在线视频| 天天操日日干夜夜撸| 日韩大片免费观看网站| 久久国内精品自在自线图片| 国产亚洲av片在线观看秒播厂| 在线天堂中文资源库| 国产精品偷伦视频观看了| 亚洲av.av天堂| 精品午夜福利在线看| 一区二区三区乱码不卡18| 国产精品久久久久久av不卡| av在线app专区| 精品人妻熟女毛片av久久网站| 国产高清不卡午夜福利| 婷婷色综合www| 51国产日韩欧美| 久久精品熟女亚洲av麻豆精品| 国产精品久久久久久久电影| 免费观看a级毛片全部| 亚洲丝袜综合中文字幕| 人成视频在线观看免费观看| 少妇高潮的动态图| 99热国产这里只有精品6| 色吧在线观看| 两个人看的免费小视频| 97人妻天天添夜夜摸| 久久精品熟女亚洲av麻豆精品| 色5月婷婷丁香| h视频一区二区三区| 91精品三级在线观看| 国产高清三级在线| 欧美日本中文国产一区发布| 亚洲精品自拍成人| 少妇人妻久久综合中文| 免费黄频网站在线观看国产| 亚洲国产精品一区三区| 免费观看性生交大片5| 久久精品久久精品一区二区三区| 97在线视频观看| 制服诱惑二区| 成人毛片60女人毛片免费| 伦精品一区二区三区| 亚洲国产毛片av蜜桃av| 侵犯人妻中文字幕一二三四区| 久久婷婷青草| 丰满饥渴人妻一区二区三| 99久久人妻综合| 国产免费现黄频在线看| 亚洲国产欧美在线一区| 老司机影院成人| 成人综合一区亚洲| 大香蕉久久成人网| 男男h啪啪无遮挡| 久久精品国产亚洲av天美| videosex国产| 日韩中字成人| 99久久精品国产国产毛片| 天天影视国产精品| 亚洲精品视频女| 久久ye,这里只有精品| 建设人人有责人人尽责人人享有的| 国产精品不卡视频一区二区| 视频区图区小说| 丝袜美足系列| 国产又爽黄色视频| 最新的欧美精品一区二区| 青春草亚洲视频在线观看| 性色av一级| 精品人妻熟女毛片av久久网站| 欧美人与性动交α欧美精品济南到 | 免费观看在线日韩| 国产成人精品婷婷| 欧美3d第一页| 国产一区二区激情短视频 | 亚洲情色 制服丝袜| 免费大片黄手机在线观看| 人体艺术视频欧美日本| 2022亚洲国产成人精品| 欧美日韩精品成人综合77777| 一本色道久久久久久精品综合| 在线观看国产h片| 亚洲精品久久午夜乱码| videossex国产| 黄网站色视频无遮挡免费观看| 精品99又大又爽又粗少妇毛片| a级片在线免费高清观看视频| 国产成人午夜福利电影在线观看| 久久精品国产亚洲av涩爱| 中文字幕另类日韩欧美亚洲嫩草| 大香蕉久久成人网| 美女主播在线视频| 国产男女内射视频| 综合色丁香网| 最近手机中文字幕大全| 麻豆乱淫一区二区| 18禁观看日本| 欧美精品高潮呻吟av久久| 亚洲成av片中文字幕在线观看 | 熟女电影av网| 欧美精品av麻豆av| 亚洲国产欧美日韩在线播放| 天堂中文最新版在线下载| 亚洲欧洲日产国产| 啦啦啦啦在线视频资源| 国产免费现黄频在线看| 久久人人爽人人爽人人片va| 欧美3d第一页| 成年美女黄网站色视频大全免费| 欧美精品av麻豆av| 亚洲伊人色综图| 国产精品久久久久久久电影| 亚洲欧洲日产国产| 曰老女人黄片| 三上悠亚av全集在线观看| 久久久久久久国产电影| 国产精品国产三级国产专区5o| 在线免费观看不下载黄p国产| 人妻少妇偷人精品九色| 日韩av免费高清视频| 丰满乱子伦码专区| 亚洲欧美日韩卡通动漫| 一区二区三区乱码不卡18| 久久久久网色| 黄色 视频免费看| 亚洲丝袜综合中文字幕| 女性生殖器流出的白浆| 只有这里有精品99| 少妇的逼好多水| 精品卡一卡二卡四卡免费| 精品人妻一区二区三区麻豆| 一区二区三区精品91| 91精品国产国语对白视频| 少妇精品久久久久久久| 一区在线观看完整版| 国产免费一区二区三区四区乱码| 少妇的逼水好多| 观看av在线不卡| 一本久久精品| 99国产精品免费福利视频| 精品一区二区免费观看| a级毛色黄片| 岛国毛片在线播放| 多毛熟女@视频| 妹子高潮喷水视频| 亚洲av日韩在线播放| 男女高潮啪啪啪动态图| 三上悠亚av全集在线观看| 99视频精品全部免费 在线| √禁漫天堂资源中文www| 欧美丝袜亚洲另类| 欧美最新免费一区二区三区| 国产高清国产精品国产三级| 天天躁夜夜躁狠狠躁躁| 亚洲国产精品一区二区三区在线| 久久热在线av| 久久国产精品男人的天堂亚洲 | 午夜精品国产一区二区电影| 一级,二级,三级黄色视频| 久久综合国产亚洲精品| 蜜桃国产av成人99| 国产在线视频一区二区| 国产精品人妻久久久影院| 精品少妇内射三级| 日本欧美视频一区| 国产熟女午夜一区二区三区| 九色亚洲精品在线播放| 精品国产一区二区三区久久久樱花| 国产精品三级大全| 在线亚洲精品国产二区图片欧美| 日韩av不卡免费在线播放| 最近中文字幕高清免费大全6| 丝袜喷水一区| 精品国产乱码久久久久久小说| 国产精品熟女久久久久浪| 国产伦理片在线播放av一区| 亚洲综合色网址| 999精品在线视频| 狠狠婷婷综合久久久久久88av| 成人18禁高潮啪啪吃奶动态图| 丝瓜视频免费看黄片| 伊人亚洲综合成人网| 黄色怎么调成土黄色| 涩涩av久久男人的天堂| 男人操女人黄网站| 少妇人妻精品综合一区二区| 免费观看在线日韩| 91精品国产国语对白视频| 亚洲三级黄色毛片| 色婷婷av一区二区三区视频| 亚洲欧美日韩另类电影网站| 国产免费福利视频在线观看| 大片免费播放器 马上看| 午夜视频国产福利| 国产一区亚洲一区在线观看| 日韩制服丝袜自拍偷拍| 国产一区二区三区av在线| 欧美人与性动交α欧美软件 | av电影中文网址| 97超碰精品成人国产| 少妇人妻 视频| 最近的中文字幕免费完整| 国产成人精品福利久久| 中文字幕最新亚洲高清| 欧美97在线视频| 少妇被粗大猛烈的视频| 青春草国产在线视频| 成人亚洲欧美一区二区av| 成人影院久久| 久久婷婷青草| 少妇的丰满在线观看| 婷婷色av中文字幕| 视频在线观看一区二区三区| 老司机影院成人| 黄色一级大片看看| 制服人妻中文乱码| 日本欧美视频一区| 久久久久久伊人网av| 麻豆精品久久久久久蜜桃| 香蕉丝袜av| 色视频在线一区二区三区| 夜夜爽夜夜爽视频| 十分钟在线观看高清视频www| 韩国高清视频一区二区三区| 日韩人妻精品一区2区三区| 大片免费播放器 马上看| 亚洲精品一二三| 爱豆传媒免费全集在线观看| av线在线观看网站| 波多野结衣一区麻豆| 亚洲国产色片| 天堂中文最新版在线下载| 久久97久久精品| 精品一品国产午夜福利视频| 日韩三级伦理在线观看| 亚洲国产欧美日韩在线播放| 91国产中文字幕| 女性被躁到高潮视频| a级片在线免费高清观看视频| 爱豆传媒免费全集在线观看| 97在线人人人人妻| 香蕉国产在线看| 国产精品久久久久久精品电影小说| 久久久国产精品麻豆| 成人影院久久| 考比视频在线观看| 国产激情久久老熟女| 九九爱精品视频在线观看| 只有这里有精品99| 亚洲五月色婷婷综合| 免费观看在线日韩| videossex国产| 精品少妇黑人巨大在线播放| 丰满迷人的少妇在线观看| 国产免费又黄又爽又色| 亚洲成国产人片在线观看| 亚洲精品国产av蜜桃| 最新的欧美精品一区二区| 好男人视频免费观看在线| 成年女人在线观看亚洲视频| 免费高清在线观看视频在线观看| 十分钟在线观看高清视频www| 午夜老司机福利剧场| 夜夜爽夜夜爽视频| a级毛片在线看网站| 国产精品三级大全| 欧美精品高潮呻吟av久久| 日本午夜av视频| 最近2019中文字幕mv第一页| 欧美精品一区二区大全| 精品一区二区三区视频在线| 国产免费福利视频在线观看| 99久久精品国产国产毛片| 九草在线视频观看| 久久热在线av| 亚洲精华国产精华液的使用体验| 一级a做视频免费观看| 国产在线一区二区三区精| 国产成人免费无遮挡视频| 97超碰精品成人国产| 一级片'在线观看视频| 亚洲图色成人| av免费观看日本| 日韩 亚洲 欧美在线| 欧美xxⅹ黑人| 国产精品久久久久久av不卡| 欧美精品高潮呻吟av久久| av网站免费在线观看视频| 丝袜人妻中文字幕| 国产成人精品在线电影| 亚洲国产av新网站| 啦啦啦视频在线资源免费观看| 精品亚洲乱码少妇综合久久| 日韩制服骚丝袜av| 国产在线一区二区三区精| 69精品国产乱码久久久| 久久99热6这里只有精品| 一级,二级,三级黄色视频| av电影中文网址| 成人亚洲精品一区在线观看| 中文字幕av电影在线播放| 人人妻人人爽人人添夜夜欢视频| 国产视频首页在线观看| 成人午夜精彩视频在线观看| 国产成人精品婷婷| 免费人成在线观看视频色| 桃花免费在线播放| 男女午夜视频在线观看 | 久久人人爽人人片av| 满18在线观看网站| 国语对白做爰xxxⅹ性视频网站| 国产成人精品福利久久| 黄片播放在线免费| 久久精品国产亚洲av涩爱| www.熟女人妻精品国产 | 国产精品女同一区二区软件| 伦精品一区二区三区| 国产高清国产精品国产三级| 宅男免费午夜| 2018国产大陆天天弄谢| 日韩欧美一区视频在线观看| 欧美精品国产亚洲| 青春草视频在线免费观看| 五月玫瑰六月丁香| 夜夜爽夜夜爽视频| 国产激情久久老熟女| 欧美97在线视频| 我的女老师完整版在线观看| 丁香六月天网| 在线观看三级黄色| 夜夜爽夜夜爽视频| 男女边吃奶边做爰视频| 免费看不卡的av| 久久久国产一区二区| 亚洲第一av免费看| 日本猛色少妇xxxxx猛交久久| 久久国产精品男人的天堂亚洲 | a级片在线免费高清观看视频| 男女高潮啪啪啪动态图| 欧美激情 高清一区二区三区| 亚洲欧洲精品一区二区精品久久久 | 一级a做视频免费观看| 建设人人有责人人尽责人人享有的| 国产精品国产av在线观看| 欧美bdsm另类| 9热在线视频观看99| 亚洲一码二码三码区别大吗| 下体分泌物呈黄色| 亚洲av中文av极速乱| 侵犯人妻中文字幕一二三四区| 精品人妻偷拍中文字幕| 人妻系列 视频| 亚洲精品视频女| 少妇人妻精品综合一区二区| 日本与韩国留学比较| 欧美成人午夜精品| 亚洲熟女精品中文字幕| 国产爽快片一区二区三区| 亚洲精品日韩在线中文字幕| 人妻系列 视频| 美女大奶头黄色视频| 美女国产高潮福利片在线看| 亚洲精品自拍成人| 超碰97精品在线观看| 午夜av观看不卡| 黄色 视频免费看| 哪个播放器可以免费观看大片| 飞空精品影院首页| av免费观看日本| 中文字幕制服av| 日韩精品有码人妻一区| 丁香六月天网| 少妇的逼好多水| 秋霞伦理黄片| 一本—道久久a久久精品蜜桃钙片| 久久精品国产亚洲av天美| 亚洲国产av影院在线观看| av在线app专区| 最近最新中文字幕免费大全7| 国产亚洲精品第一综合不卡 | 免费在线观看完整版高清| 天堂8中文在线网| 亚洲,欧美精品.| 18禁裸乳无遮挡动漫免费视频| 免费看av在线观看网站| 香蕉丝袜av| 欧美精品av麻豆av| 啦啦啦啦在线视频资源| 欧美人与善性xxx| 美女主播在线视频| 一本久久精品| 永久网站在线| 午夜激情av网站| 国产黄色免费在线视频| 欧美3d第一页| 一区二区av电影网| 久久国产精品男人的天堂亚洲 | 熟女av电影| 美女xxoo啪啪120秒动态图| 99国产精品免费福利视频| 一区二区三区四区激情视频| 日韩熟女老妇一区二区性免费视频| 国产免费一区二区三区四区乱码| 寂寞人妻少妇视频99o| 黄色视频在线播放观看不卡| 中文欧美无线码| 中文字幕制服av| www.色视频.com| 一级爰片在线观看| 大码成人一级视频| kizo精华| 久久精品久久精品一区二区三区| 成人亚洲欧美一区二区av| 大香蕉97超碰在线| 这个男人来自地球电影免费观看 | 亚洲欧美日韩另类电影网站| 免费观看a级毛片全部| 高清毛片免费看| 日本wwww免费看| 亚洲国产成人一精品久久久| 国产精品成人在线| a级毛片黄视频| 老司机影院毛片| 91久久精品国产一区二区三区| 九九爱精品视频在线观看| 久久久久久伊人网av| 巨乳人妻的诱惑在线观看| 欧美少妇被猛烈插入视频| 人人妻人人爽人人添夜夜欢视频| 99久久综合免费| 永久网站在线| 欧美成人午夜精品| 视频区图区小说| 久久久a久久爽久久v久久| 日本猛色少妇xxxxx猛交久久| 熟女av电影| 日日摸夜夜添夜夜爱| 九九在线视频观看精品| 最近的中文字幕免费完整| 午夜av观看不卡| 成年av动漫网址| 桃花免费在线播放| 亚洲人成网站在线观看播放| 黄色毛片三级朝国网站| 国产成人精品久久久久久| 在线免费观看不下载黄p国产| 哪个播放器可以免费观看大片| 18禁观看日本| 国产成人精品婷婷| 在线精品无人区一区二区三| 丰满少妇做爰视频| 亚洲激情五月婷婷啪啪| 国产欧美日韩一区二区三区在线| 五月玫瑰六月丁香| 亚洲国产精品999| 美女福利国产在线| 亚洲精品aⅴ在线观看| 久久久精品区二区三区| 久久久久久伊人网av| 亚洲丝袜综合中文字幕| 免费观看性生交大片5| 色网站视频免费| a 毛片基地| 国产 一区精品| 99久久人妻综合| 国产国拍精品亚洲av在线观看| 国产成人一区二区在线| 亚洲婷婷狠狠爱综合网| 精品一区在线观看国产| 日本黄色日本黄色录像| 亚洲四区av| 超色免费av| 99久久人妻综合| 国产精品免费大片| 在线天堂中文资源库| 一区二区av电影网| 男女无遮挡免费网站观看| 人人澡人人妻人| 色网站视频免费| 亚洲欧美一区二区三区国产| 免费在线观看黄色视频的| 天天影视国产精品| 观看美女的网站| 99精国产麻豆久久婷婷| 国产黄色视频一区二区在线观看| 26uuu在线亚洲综合色| 天天影视国产精品| 午夜免费鲁丝| 制服丝袜香蕉在线| 国产精品久久久久久精品古装| 国产成人免费观看mmmm| 宅男免费午夜| 性色avwww在线观看| 男女啪啪激烈高潮av片| 三上悠亚av全集在线观看| 亚洲伊人久久精品综合| 乱码一卡2卡4卡精品| 亚洲av中文av极速乱| 又粗又硬又长又爽又黄的视频| 自线自在国产av| 国产熟女午夜一区二区三区| 国产精品蜜桃在线观看| 亚洲欧美成人综合另类久久久| 久久久久久人妻| 国产麻豆69| 国产深夜福利视频在线观看| 久久这里只有精品19| 97在线人人人人妻| 亚洲一级一片aⅴ在线观看| 国产日韩欧美在线精品| av又黄又爽大尺度在线免费看| 国产精品蜜桃在线观看| 国产麻豆69| 国产xxxxx性猛交| 男女边吃奶边做爰视频| 成人午夜精彩视频在线观看| 国产欧美另类精品又又久久亚洲欧美| 高清在线视频一区二区三区| 亚洲av.av天堂| 久久精品国产a三级三级三级| 极品人妻少妇av视频| 日本91视频免费播放| 亚洲av.av天堂| 久久久久久久亚洲中文字幕| 精品久久蜜臀av无| 亚洲欧美色中文字幕在线| 亚洲综合色惰| 精品亚洲成国产av| 精品午夜福利在线看| 久久精品熟女亚洲av麻豆精品| 九色成人免费人妻av| 久久久久国产网址| 97人妻天天添夜夜摸| 亚洲欧洲国产日韩| 18+在线观看网站| 性色avwww在线观看| 国产黄频视频在线观看| 久久久久久久亚洲中文字幕| 久久青草综合色| 交换朋友夫妻互换小说| 自线自在国产av| 国产片内射在线| 99视频精品全部免费 在线| 久久99热6这里只有精品| 亚洲精品色激情综合| 亚洲国产日韩一区二区| 97人妻天天添夜夜摸| 国产精品秋霞免费鲁丝片| 蜜桃在线观看..| 最近手机中文字幕大全| 日本色播在线视频| 久久这里有精品视频免费| 久久午夜福利片| 在线观看免费日韩欧美大片| 午夜影院在线不卡| 中文字幕av电影在线播放| 91午夜精品亚洲一区二区三区| 高清在线视频一区二区三区| 天堂8中文在线网| 国产免费一级a男人的天堂| 熟妇人妻不卡中文字幕| 久久久久人妻精品一区果冻| 天堂中文最新版在线下载| 女的被弄到高潮叫床怎么办| 欧美另类一区| 全区人妻精品视频| 欧美成人精品欧美一级黄| 国国产精品蜜臀av免费| 熟女电影av网| 欧美日韩亚洲高清精品| 丰满乱子伦码专区| 你懂的网址亚洲精品在线观看| 如何舔出高潮| 欧美少妇被猛烈插入视频| 九九在线视频观看精品| 香蕉精品网在线| 一级毛片电影观看| 国产成人精品在线电影| 啦啦啦啦在线视频资源| 国产精品免费大片| 精品国产一区二区三区久久久樱花| 亚洲成人一二三区av| 国产精品免费大片| 九九在线视频观看精品| 欧美 日韩 精品 国产| 男女高潮啪啪啪动态图| 免费女性裸体啪啪无遮挡网站| 久久久久久久国产电影| 制服人妻中文乱码| 国产免费一级a男人的天堂| 乱人伦中国视频| 日本av手机在线免费观看| 国产成人精品无人区| 亚洲国产精品国产精品| 看免费av毛片| 婷婷色麻豆天堂久久| 巨乳人妻的诱惑在线观看| 热re99久久国产66热| 两性夫妻黄色片 | 国产av码专区亚洲av| 最近的中文字幕免费完整| 久久精品国产自在天天线| 最近的中文字幕免费完整| 国产精品.久久久| 中文乱码字字幕精品一区二区三区| 亚洲熟女精品中文字幕| 欧美97在线视频| 青青草视频在线视频观看|